Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NRx Pharma

What's Next For NRx Pharma As FDA Denies Breakthrough Therapy Tag For COVID-19 Therapy

The FDA has denied NRx Pharmaceuticals Inc's (NASDAQ:NRXP) Breakthrough Therapy designation (BTD) request for Zyesami (aviptadil). The request for BTD was submitted based on a post-hoc subgroup analysis of patients who, in addition to aviptadil or placebo, were also treated with Gilead Sciences Inc's (NASDAQ: GILD) remdesivir and whose respiratory failure due to critical COVID-19 continued…

Benzinga · Jun 13, 2022

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · May 26, 2022

NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy

NRx Pharmaceuticals Inc (NASDAQ:NRXP) has filed a new Breakthrough Therapy designation request with the FDA for Zyesami focused on a subgroup of critical COVID-19 patients. The subgroup includes patients who were also treated with Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir) in addition to aviptadil or placebo. The request includes safety data on approximately 750 patients…

Benzinga · Apr 21, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped

Quantum Leap Healthcare Collaborative (QLHC) announced that the nebulized form of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (Aviptadil) in the I-SPY COVID Trial of

Benzinga · Mar 31, 2022

NRx Pharmaceuticals Raises $25M Via Equity To Support Its Pipeline Development

NRx Pharmaceuticals (NASDAQ: NRXP) has announced the private placement of 7.8 million shares priced at a premium to market under Nasdaq rule, for

Benzinga · Jan 31, 2022

NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19

NRx Pharmaceuticals (NASDAQ: NRXP) has

Benzinga · Jan 26, 2022

NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments

NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its

Benzinga · Jan 18, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

422,577 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.